These trials are currently recruiting subjects and are available through the BMC Parkinson's Disease and Movement Disorders Center.

For information, please contact Ray James, RN at 617.638.7745.

- [Parkinson's Progression Markers Initiative (PPMI) ](https://www.bumc.bu.edu/parkinsonsdisease/files/2021/01/PPMI-BU-Edited-Flyer-1_14_21.pdf)
- [Study in Parkinson Disease of Exercise Phase 3 Clinical Trial (SPARX3) ](https://www.bumc.bu.edu/parkinsonsdisease/files/2021/09/SPARX3-Flyer-APPROVED.pdf)
- [A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of BIIB122 in Participants with Parkinson’s Disease (LUMA) ](https://www.bumc.bu.edu/parkinsonsdisease/files/2023/06/LUMA-Study-BUMC-2023.pdf)
- [Trial of Parkinson’s and Zoledronic Acid (TOPAZ) ](https://www.bumc.bu.edu/parkinsonsdisease/files/2021/07/TOPAZ-Recruitment-Postcard-Stamped.pdf)
- [Fostering Inclusivity in Research Engagement for Underrepresented Populations in Parkinson's Disease (FIRE-UP PD)](https://www.bumc.bu.edu/parkinsonsdisease/files/2019/11/FireUp-PD.pdf)
- [Biomarker Study (SEARCH PD)](https://www.bumc.bu.edu/parkinsonsdisease/files/2018/12/SEARCH-PD-Flyer-v1.0-16JAN2018-IRB-Approved-2.13.2018.pdf)